309. Deputy Mark Wall asked the Minister for Health the steps being taken to ensure urgent access to welireg (belzutifan) for a young adult with von Hippel-Lindau disease in County Kildare (details supplied) where clinicians advise that delay risks irreversible loss of neurological and functional ability; and if she will make a statement on the matter. [10622/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
315. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current stage reached in each …
316. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive or her Department has prepared, commissioned, received, or reviewed any cost-effectiveness analysis, budget impact analysis, or economic model relating to the use of GLP-1 receptor agonist medicines for obesity or weight management, including semaglutide and tirzepatide; whether any such analysis includes modelling of downstrea…
317. Deputy Ken O'Flynn asked the Minister for Health to outline the policy or decision framework used by the Health Service Executive when considering prevention-based outcomes, including reductions in the future incidence of type 2 diabetes and cardiovascular disease, in medicines reimbursement decisions under the Health (Pricing and Supply of Medical Goods) Act 2013; and whether the Department has issued, or inten…
318. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken or commissioned any assessment of the equity implications of current access arrangements for GLP-1 receptor agonist medicines for obesity or weight management, including the extent to which access is determined by capacity to pay out of pocket rather than clinical need; and whether the forthcoming national obesity strategy wil…
320. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department on whether GLP-1 receptor agonist medicines for obesity or weight management should be eligible for reimbursement under the Drugs Payment Scheme, subject to health technology assessment and clinical governance; whether any policy review is under way in the context of the development of the new national obesity strategy…
321. Deputy Ken O'Flynn asked the Minister for Health whether the national obesity strategy currently in development will explicitly address the role of pharmacological treatment for obesity, including eligibility, reimbursement pathways, and equity of access; and whether she will outline how medicines policy is being aligned with the objectives of that strategy. [10660/26]
344. Deputy David Cullinane asked the Minister for Health the number and the details of medications and medical products approved for reimbursement, but which received a recommendation to not consider the product for recommendation from an agency (details supplied), in tabular form. [10723/26]
345. Deputy David Cullinane asked the Minister for Health the reason pluvicto was not approved for reimbursement but luthathera received approval; and if she will make a statement on the matter. [10724/26]
1135. Deputy Aindrias Moynihan asked the Minister for Health when a NCPE re-commenced assessment will be completed (details supplied); and if she will make a statement on the matter. [10188/26]
1159. Deputy Shane Moynihan asked the Minister for Health for an update on the accessibility of Welireg (belzutifan) for patients with von Hippel-Lindau disease; and if she will make a statement on the matter. [10252/26]
1190. Deputy Pádraig Rice asked the Minister for Health the current reimbursement arrangements in place for GLP-1 medications; to identify the products currently available under each scheme and the criteria for access; if there are plans to expand access; if further products are undergoing pricing and reimbursement assessment; if so, the status of that work; and if she will make a statement on the matter. [10332/26]
1204. Deputy Mark Ward asked the Minister for Health if welireg is available to public HSE patients with von Hippel-Lindau disease; the way they can access this treatment; the alternative treatments that are offered through the HSE; and if she will make a statement on the matter. [10417/26]
984. Deputy Mairéad Farrell asked the Minister for Health the steps she has taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the safeguards currently in place to protect such patients from avoidable permanent harm during administrative delays; …
986. Deputy Paula Butterly asked the Minister for Health the measures being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel–Lindau disease, in circumstances where clinicians warn that any delay risks irreversible neurological and functional decline; if compassionate or exceptional access pathways are available pending completion of national reimbursement processes; and the safe…
1020. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has undertaken, commissioned, or reviewed any health economic or cost-benefit analysis on the use of GLP-1 receptor agonist medicines, including tirzepatide and semaglutide, for obesity treatment and the prevention of type 2 diabetes; if so, the details and outcomes of any such analysis; and if not, whether she intends to commiss…
1021. Deputy Ken O'Flynn asked the Minister for Health the current policy position of her Department regarding the reimbursement of GLP-1 receptor agonist medicines under the Drugs Payment Scheme; whether any review is under way to consider broader eligibility criteria; and the expected timeline for any decision on changes to reimbursement policy. [7677/26]
1022. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed the potential impact of GLP-1 receptor agonist medicines on reducing the future incidence of type 2 diabetes, cardiovascular disease, and associated complications; whether such preventative outcomes are factored into medicines reimbursement decisions; and if she will outline how prevention-based savings are weighted in funding …
1023. Deputy Ken O'Flynn asked the Minister for Health what consideration has been given to the equity implications of high out-of-pocket costs for GLP-1 receptor agonist medicines; whether the Department has examined the risk of access being determined by ability to pay rather than clinical need; and if she will outline any measures under consideration to address this issue. [7679/26]
1037. Deputy Carol Nolan asked the Minister for Health if she will intervene to support the case of a person (details supplied) in urgent need of life-saving medication; and if she will make a statement on the matter. [7717/26]
1047. Deputy Ann Graves asked the Minister for Health the steps which are being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; and the safeguard…
1053. Deputy Eamon Scanlon asked the Minister for Health the steps being taken to ensure urgent access to Welireg (belzutifan) for a young adult with von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; whether compassionate or exceptional access mechanisms are available while national reimbursement processes are ongoing; the safeguards which are…
1058. Deputy Mark Wall asked the Minister for Health if she will provide access to a medicine for the urgent case of a person (details supplied). [7780/26]
1059. Deputy Mark Wall asked the Minister for Health the steps being taken to ensure urgent access to Welireg (belzutifan) for a young adult with Von Hippel-Lindau disease where clinicians advise that delay risks irreversible loss of neurological and functional ability; and the safeguards currently in place to protect such patients from avoidable permanent harm during administrative delays. [7781/26]
1062. Deputy John Connolly asked the Minister for Health the steps being taken to ensure access to Welireg (belzutifan) for patients with Von Hippel–Lindau disease whose treating clinicians advise that delay risks irreversible neurological and functional decline; if compassionate or exceptional access mechanisms are available; and if she will make a statement on the matter. [7800/26]